Fairvalue-Calculator Fairvalue-Calculator
EN DE

Egetis Therapeutics AB (EGTX) Fair Value & Analysis

Healthcare · SE · Market cap 2.6B SEK

Pricekr 5.47
Fair Valuekr 3.28
Upside-40.0%
Quality95/100
Evidence: Low Range kr 2.46 – kr 4.10

Fair value as of: Jun 24, 2026

Analysis

Egetis Therapeutics AB (EGTX) currently trades at kr 5.47, while our model-based Fair Value estimate is kr 3.28 — implying the stock looks roughly 40.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Egetis Therapeutics AB (EGTX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 3.28 versus a price of kr 5.47 — about −40% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EGTX?
Our 21-model fair value for Egetis Therapeutics AB is kr 3.28 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 5.47.
What is the quality score of EGTX?
Egetis Therapeutics AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.